Literature DB >> 23265436

Tumor budding, myofibroblast proliferation, and fibrosis in obstructing colon carcinoma: the roles of Hsp47 and basic fibroblast growth factor.

Chuan-Jie Xu1, Tetuo Mikami, Takatoshi Nakamura, Tomoko Tsuruta, Norihiro Nakada, Nobuyuki Yanagisawa, Shi-Xu Jiang, Isao Okayasu.   

Abstract

This study was designed to assess the mechanism of obstruction in obstructing colorectal carcinomas. Thirty-five cases of obstructing colorectal carcinoma and 34 cases of non-obstructing carcinoma were studied. The lesions were immunohistochemically analyzed using antibodies for pan-cytokeratin, α-smooth muscle actin, matrix metalloproteinase-7, 47-kDa heat shock protein (Hsp47), basic fibroblast growth factor (bFGF), myeloperoxidase, and CD68. Compared with non-obstructing cases, obstructing carcinoma cases included lesions of poorer differentiation. A higher value of tumor budding was observed in obstructing than in non-obstructing carcinoma. A higher number of α-smooth muscle actin-positive myofibroblasts, a higher expression of Hsp47 in stromal spindle cells, and a higher expression of bFGF in inflammatory cells were also significant in obstructing carcinoma. Therefore, obstructing colon carcinomas were characterized by poorer differentiation of cancer cells, a high level of tumor budding, and stromal myofibroblast proliferation resulting in fibrosis. Correlative Hsp47 expression in fibroblasts with bFGF in inflammatory cells may contribute to stromal fibrosis.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23265436     DOI: 10.1016/j.prp.2012.10.008

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  7 in total

1.  Effect of CPU-XT-008, a combretastatin A-4 analogue, on the proliferation, apoptosis and expression of vascular endothelial growth factor and basic fibroblast growth factor in human umbilical vein endothelial cells.

Authors:  Rui Xiong; Jing Sun; Kun Liu; Yungen Xu; Shuying He
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

Review 2.  The heat shock protein 47 as a potential biomarker and a therapeutic agent in cancer research.

Authors:  Beatriz Dal Pont Duarte; Diego Bonatto
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-20       Impact factor: 4.553

3.  Surveillance for early stages of colon cancer: potentials for optimizing follow-up protocols.

Authors:  Elisa Gilardoni; Davide Paolo Bernasconi; Silvia Poli; Mattia Garancini; Margherita Luperto; Nicola Zucchini; Giorgio Bovo; Mauro Totis; Alvaro Bugatti; Luca Gianotti
Journal:  World J Surg Oncol       Date:  2015-08-28       Impact factor: 2.754

Review 4.  Newly recognized extratumoral features of colorectal cancer challenge the current tumor-node-metastasis staging system.

Authors:  Elias Athanasakis; Sofia Xenaki; Maria Venianaki; George Chalkiadakis; Emmanuel Chrysos
Journal:  Ann Gastroenterol       Date:  2018-06-19

Review 5.  Tumour budding in rectal cancer. A comprehensive review.

Authors:  Leonardo S Lino-Silva; Rosa A Salcedo-Hernández; Armando Gamboa-Domínguez
Journal:  Contemp Oncol (Pozn)       Date:  2018-06-30

Review 6.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12

7.  Presence of heat shock protein 47-positive fibroblasts in cancer stroma is associated with increased risk of postoperative recurrence in patients with lung cancer.

Authors:  Takuto Miyamura; Noriho Sakamoto; Kaori Ishida; Tomoyuki Kakugawa; Hirokazu Taniguchi; Yoshiko Akiyama; Daisuke Okuno; Atsuko Hara; Takashi Kido; Hiroshi Ishimoto; Takuro Miyazaki; Keitaro Matsumoto; Tomoshi Tsuchiya; Hiroyuki Yamaguchi; Taiga Miyazaki; Yasushi Obase; Yuji Ishimatsu; Takeshi Nagayasu; Hiroshi Mukae
Journal:  Respir Res       Date:  2020-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.